Hanmi In Tough Spot After Sanofi Efpeglenatide U-Turn
New Partners, Strategy Needed?
Sanofi’s decision to return to originator Hanmi all rights to the novel diabetes candidate efpeglenatide, which is in global Phase III trials, has placed the South Korean pharma in a difficult spot. Unless there are some surprisingly positive data, finding a major global partner for commercialization may be tough.
